Hikma Pharmaceuticals (GB:HIK) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hikma Pharmaceuticals has announced the strategic acquisition of Xellia Pharmaceuticals’ US finished dosage form business, expanding its injectables portfolio and manufacturing capabilities with a $135 million initial payment and up to $50 million in milestones. The deal includes a commercial portfolio, a Cleveland manufacturing plant, and an R&D center in Croatia, expected to enhance Hikma’s growth and injectable medicine production. The acquisition is projected to be earnings-neutral initially but accretive over the longer term, with an immediate revenue contribution of approximately $75 million annually from Xellia’s current products.
For further insights into GB:HIK stock, check out TipRanks’ Stock Analysis page.